Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. |
| |
Authors: | D J Wells K E Wells F S Walsh K E Davies G Goldspink D R Love P Chan-Thomas M G Dunckley T Piper G Dickson |
| |
Affiliation: | Department of Veterinary Basic Sciences, Royal Veterinary College, London, UK. |
| |
Abstract: | Duchenne and the less severe Becker form of muscular dystrophy (DMD,BMD) result from genetic deficiency in the level and/or activity of the protein dystrophin. The recent availability of cDNA based minigenes encoding recombinant dystrophin polypeptides has raised the possibility of somatic gene transfer as a therapeutic approach to treat dystrophin deficiency. In this respect, the mdx mouse provides a useful model of DMD exhibiting features characteristic of both the early myopathic and later fibrotic phases of the human disease. Using a mutated human cDNA, compatible in size with virus-based somatic gene transfer vectors, the pathophysiological consequences of restoring dystrophin expression have been examined in transgenic mdx mice. Transgene expression was correlated with a marked reduction of the skeletal myofibre necrosis and regeneration which is a major feature of the dystrophin-deficient phenotype in young mdx mice. The cDNA construct which is based on a very mild BMD phenotype thus encodes a highly functional dystrophin molecule whose reduced size renders it an attractive candidate for development as a therapeutic gene transfer reagent. |
| |
Keywords: | |
本文献已被 Oxford 等数据库收录! |
|